Abstract
In a prospective study performed between June 1992 and March 1994 19 eyes of 19 patients with dense fibrinous pupillary membranes following cataract surgery were treated with intracameral injections of 25μg recombinant tissue plasminogen activator (r-tPA). Injections were performed between the second and twenty-third postoperative day (mean 5.6±6.9 days). Complete fibrinolysis within one to 4 hours (mean: 3.3±0.89 hours) was observed in 18 (94.7%) eyes. In one (5.3%) eye fibrinolysis was incomplete despite a second injection. In 2 (10.5%) eyes recurrence of a distinct fibrinous membrane was noted which then cleared spontaneously with topical treatment. A small hyphema developed in 2 (10.5%) eyes and intraocular pressure exceeded 25 mm Hg in 2 (10.5%) eyes. No increase of keratopathy nor any toxic intraocular side effect of 25μg intracameral r-tPA was observed throughout the study. The intracameral injection of r-tPA clinically proved to safely accelerate the resorption of dense fibrinous membranes following cataract surgery and thus enhance visual recovery minimizing subsequent complications and systemic or subconjunctival anti-inflammatory treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agnelli B, Buchanan MR, Fernandez F et al. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985; 72: 178–82.
Collen D, Stassen JM, Marafino BJ et al. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 1984; 231: 146–52.
Lambrou FH, Snyder RW, Williams GA et al. Treatment of experimental intravitreal fibrin with tissue plasminogen activator. Am J Ophthalmol 1987; 104: 619–23.
Snyder RW, Lambrou FH, Williams GA. Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Arch Ophthalmol 1987; 105: 1277–80.
Fourman S, Vaid K. Effects of tissue plasminogen activator on glaucoma filter blebs in rabbits. Ophthalmic Surg 1989; 20: 663–7.
Ozment RR, Liaw ZC, Krug J et al. Use of tissue plasminogen activator in experimental filtration surgery. Invest Ophthalmol Vis Sci 1989; 30 (Suppl): 418.
Strauss GH, Dunn ET, Dünn RC et al. Subconjunctival high dose plasminogen activator in rabbit filtration surgery. J Ocul Pharmacol 1991;7: 9–19.
Lambrou FH, Snyder RW, Williams GA. Use of tissue plasminogen activator in experimental hyphema. Arch Ophthalmol 1987; 105: 995–7.
Howard GR, Vukich J, Fiscella RG et al. Intraocular tissue plasminogen activator in a rabbit model of traumatic hyphema. Arch Ophthalmol 1991; 109: 272–4.
Irvine WD, Johnson MW, Hernandez E, Olsen KR. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol 1991; 109: 718–22.
Johnson MW, Olsen KR, Hernandez E et al. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990; 108: 259–63.
Jaffe GL, Abrams GW, Williams GA, Han DP. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology 1990; 97: 184–9.
Snyder RW, Sherman MD, Allison RW. Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty. Am J Ophthalmol 1990; 109: 483–4.
Körner F, Boehnke M. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis. German J Ophthalmol 1992; 1: 354–60.
Baziuk N, Fang T, Peyman GA, Gremillion CM Jr. Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis. Intern Ophthalmol 1991; 15: 79–86.
Wedrich A, Ries E, Stolba U, Binder S. Die Anwendung von r-tPA bei postoperativer Endophthalmitis nach Kataraktoperation. Spektrum Augenheilkd: in press.
Lesser GR, Osher RH, Whipple D et al. Treatment of anterior chamber fibrin following cataract surgery with tissue plasminogen activator. J Cat Refract Surg 1993; 19: 301–5.
Moon J, Chung S, Myong Y et al. Treatment of postcataract fibrinous membranes with tissue plasminogen activator. Ophthalmology 1992; 99: 1256–9.
Tripathi BJ, Geanon JD, Tripathi RC. Distribution of tissue plasminogen activator in human and monkey eyes. An immunohistochemical study. Ophthalmology 1987; 94: 1434–8.
Tripathi RC, Park JK, Tripathi BJ, Millard CB. Tissue plasminogen activator in human aqueous and its possible therapeutic significance. Am J Ophthalmol 1988; 106: 719–22.
Yoshitomi F, Utsumi E, Hayashi M et al. Postoperative fluctuations of tissue plasminogen activator (t-PA) in aqueous humor of pseudophakes. J Cat Refract Surg 1991; 17: 543–6.
Menapace R, Amon M, Radax U. Evaluation of 200 consecutive IOGEL 1103 capsular bag lenses implanted through a small incision. J Cataract Refract Surg 1992; 18: 252–64.
Wedrich A, Menapace R, Radax U et al. Combined smallincision cataract surgery and trabeculectorny—technique and results. Intern Ophthalmol 1992; 16: 409–14.
Zetterström C, Olivestedt G, Lundvall A. Exfoliation syndrome and extracapsular cataract extraction with implantation of posterior chamber lens. Acta Ophthalmol 1992; 70: 85–90.
Folk JC, Hershey JM, Rivers MB. Lack of effectiveness of tissue plasminogen activator 20 or more days after vitrectomy. Arch Ophthalmol 1991; 109: 614.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wedrich, A., Menapace, R. & Mühlbauer-Ries, E. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery. Int Ophthalmol 18, 277–280 (1994). https://doi.org/10.1007/BF00917830
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00917830